ArticleBrazilian dental journal2024
Effect of local and systemic administration of atorvastatin for improving bone healing on critical defects.
Article in Brazilian dental journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Effects of rosuvastatin treatment and other statins on burn wound healing.World journal of methodology · 2026Review
- Experimental beneficial effect of rosuvastatin on burn wound healing in a rat model.World journal of experimental medicine · 2026Article
- In Vitro Release Dynamics of Atorvastatin-Loaded Alginate Particles for Enhanced Periodontal Treatment.Polymers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the impact of atorvastatin, administered both locally and systemically, on critical defects in the calvaria of rats. Thirty-six adult rats were randomly assigned to three groups, with all bone defects covered by a collagen membrane. The groups received different treatments: distilled water (GAD), where membranes were soaked in distilled water; systemic application of atorvastatin (GAS) at a dosage of 3.6mg/kg/day through gavage; and local application of atorvastatin (GAL). After 14 and 28 days, all animals were euthanized, and various assessments were conducted, including histometric analysis, measurement of linear residual defect, evaluation of newly formed bone area, determination of membrane and soft tissue area, cell count, and immunohistochemical analysis. Group GAS exhibited a significant reduction in residual defect compared to the other groups (p<0.05) and a lower number of osteocytes (p<0.05) in comparison with other groups. On day 28, both GAL and GAS groups showed a higher number of inflammatory cells compared to GAD (p<0.05). Immunolabeling of CD31 was similar for both groups, but in the case of osteocalcin, there was a significant increase in labeling for groups GAS and GAL between days 14 and 28 postoperative (p<0.05). In conclusion, systemic atorvastatin demonstrated enhanced osteogenesis in critical calvaria defects in rats, suggesting its efficacy in promoting bone regeneration without exerting a notable anti-inflammatory effect.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.